News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
It’s official: Philly Tech Week is back and IRL in 2022
The 12th annual celebration of technology, entrepreneurship and innovation will be held May 6 to 14, 2022 with a mix of in-person and virtual events.
Two Penn spinouts on the Technical.ly Philly RealLIST standout tech companies
Of the 20 companies on the Technical.ly Philly RealLIST, two are Penn spinout companies: Lumify and Neuralert.
ExynAI has been shortlisted as a finalist for a SXSW Innovation Award
For the 2022 category of Robotics and Hardware. The Exyn team will be going to Austin for the awards.
Penn’s Gene Therapy Program signs manufacturing partnership with the Center for Breakthrough Medicines
The Center for Breakthrough Medicines and Penn’s Gene Therapy Program (GTP) entered into a multi-year collaboration focusing on the manufacturing and testing of modern gene therapy processes.
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Halting Progress and Happy Accidents: How mRNA vaccines were made
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.
Cogwear is featured on the cover of the Journal of Precision Medicine
The Journal of Precision Medicine highlighted Penn spinout Cogwear’s novel technology for behavioral health applications.
Moderna forms oncology collaboration with Carisma Therapeutics
Moderna will collaborate with Penn spinout Carisma Therapeutics to discover, develop and commercialize in-vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.
From foundational discoveries to profound impact
Without the mRNA technology foundation laid by Karikó and Weissman, the Pfizer/BioNTech and Moderna vaccines being deployed across the world would not exist.
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.